5. Progressive supranuclear palsy Clinical trials / Disease details
Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04734379 (ClinicalTrials.gov) | January 22, 2021 | 18/1/2021 | Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 | A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients With the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome. | Progressive Supranuclear Palsy;Corticobasal Syndrome | Drug: Fasudil | Woolsey Pharmaceuticals | NULL | Active, not recruiting | 35 Years | 80 Years | All | 15 | Phase 2 | United States |